--- title: "Progressive Meningiomas A071401 | Sutter Health" description: "Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations" url: "https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Progressive Meningiomas A071401 # Progressive Meningiomas A071401 **Status:** Open to Enrollment [Email us to enroll](https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850#enroll) #### Study details View study details on [clinicaltrials.gov](http://clinicaltrials.gov/ct2/show/NCT02523014). #### Locations - Sutter Health System Wide #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations ![J Alex Garcia-Young, M.D., DABR](https://dyn.mktgcdn.com/p/RIg-dZQzhveYLkMBvTvxcA7bC9jo7ddl-lwgbFCb57M/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) J Alex Garcia-Young, M.D., DABR Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/j-alex-garcia-young-md-dabr-1078064877) ## Email us to enroll - [Email Sutter Health System Wide](mailto:ClinicalResearch%40sutterhealth.org?subject=More%20information%20on%20Progressive%20Meningiomas%20A071401%20in%20Sutter%20Health%20System%20Wide&body=Please%20be%20aware%20that%20if%20you%20reply%20with%20unencrypted%20email%2C%20this%20increases%20the%20risk%20that%20information%20could%20be%20read%20by%20an%20unauthorized%20third%20party.%20Please%20do%20not%20include%20any%20Protected%20Health%20Information%20in%20your%20email%20response.) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Adjuvant Grade II or III Meningioma JZP3507-202](https://www.sutterhealth.org/research/clinical-trials/adjuvant-grade-ii-or-iii-meningioma-jzp3507-202-2084405172) A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma **Status:** Open to Enrollment - Clinical trial ### [Residual, Progressive or Recurrent Grade II or III Meningioma NEO100-02](https://www.sutterhealth.org/research/clinical-trials/residual-progressive-or-recurrent-grade-ii-or-iii-meningioma-neo100-02-2066911166) An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma **Status:** Open to Enrollment - Clinical trial ### [Advanced Cervical Cancer NRG GY037](https://www.sutterhealth.org/research/clinical-trials/advanced-cervical-cancer-nrg-gy037-2097344123) A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer **Status:** Open to Enrollment - Clinical trial ### [Advanced Staged Cancer Targeted Therapy ASCO TAPUR](https://www.sutterhealth.org/research/clinical-trials/targeted-agent-and-profiling-utilization-registry-tapur-st-1049141787) Targeted Agent and Profiling Utilization Registry (TAPUR) Study **Status:** Open to Enrollment - Clinical trial ### [Adverse Effects of Chemotherapy Shengbai Solution](https://www.sutterhealth.org/research/clinical-trials/adverse-effects-of-chemotherapy-shengbai-solution-1097505286) A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Progressive Meningiomas A071401"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850#medicalwebpage","name":"Progressive Meningiomas A071401","description":"Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations","url":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850","inLanguage":"en-US","dateModified":"2026-10-26","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850#breadcrumblist"},"mentions":[{"@type":"Person","name":"J Alex Garcia-Young, M.D., DABR","url":"https://www.sutterhealth.org/research/investigators/j-alex-garcia-young-md-dabr-1078064877","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850#medicaltrial","name":"Progressive Meningiomas A071401","alternateName":"Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations","url":"https://www.sutterhealth.org/research/clinical-trials/progressive-meningiomas-a071401-2098340850","description":"Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations","identifier":"NCT02523014","code":{"@type":"MedicalCode","codeValue":"NCT02523014","codingSystem":"ClinicalTrials.gov"},"sameAs":"http://clinicaltrials.gov/ct2/show/NCT02523014","status":"https://schema.org/Recruiting","healthCondition":[{"@type":"MedicalCondition","name":"Meningioma"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sutter Health System Wide"}]} ```